This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tilvestamab, targeting AXL (AXL receptor tyrosine kinase), a member of the TAM receptor family. AXL plays a critical role in regulating cellular processes including survival, proliferation, migration, and immune modulation. Upon binding its ligand Growth Arrest-Specific 6 (GAS6), AXL activates downstream signaling pathways such as PI3K/AKT and MAPK/ERK. Aberrant AXL expression and activation have been implicated in multiple pathological conditions, particularly in cancer progression, metastasis, therapeutic resistance, and immune evasion across various malignancies including non-small cell lung cancer, acute myeloid leukemia, and triple-negative breast cancer.
Tilvestamab represents a therapeutic antibody designed to inhibit AXL signaling by blocking ligand binding and promoting receptor degradation. This biosimilar antibody provides researchers with a valuable tool for investigating AXL-mediated mechanisms in oncology, studying tumor microenvironment interactions, exploring resistance mechanisms to targeted therapies, and evaluating potential therapeutic strategies in preclinical disease models.
Email: support@cusabio.com
Distributors Worldwide